N-(3,5-DICHLORO-4-(PROP-2-YNYL)PHENYL)-N'-METHOXYFORMIMIDAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DHCVMKVVMIVIOX-UHFFFAOYSA-N
Smiles	CO\N=C\Nc1cc(Cl)c(CC#C)c(Cl)c1
InChI	InChI=1S/C11H10Cl2N2O/c1-3-4-9-10(12)5-8(6-11(9)13)14-7-15-16-2/h1,5-7H,4H2,2H3,(H,14,15)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C11H10Cl2N2O
Molecular Weight	257.12
AlogP	3.89
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	33.62
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	16.0

Assay Description	Organism	Bioactivity
Fungicidal activity against benzimidazole-resistant Botryotinia fuckeliana after 48 hr by poisoned food technique	Botryotinia fuckeliana	0.005 ppm	Fungicidal activity against benzimidazole-resistant Botryotinia fuckeliana after 48 hr by poisoned food technique	Botryotinia fuckeliana	18.2 nM
Fungicidal activity against benzimidazole-sensitive Botryotinia fuckeliana after 48 hr by poisoned food technique	Botryotinia fuckeliana	30.0 ppm
Resistance ratio of EC50 for benzimidazole-resistant Botryotinia fuckeliana to EC50 for benzimidazole-sensitive Botryotinia fuckeliana	Botryotinia fuckeliana	10.0
Ratio of DMPF EC50 to compound EC50 for benzimidazole-resistant Botryotinia fuckeliana	Botryotinia fuckeliana	600.0
1-octanol/water distribution coefficient, log P of the compound	None	3.3
Phytotoxicity against Phaseolus vulgaris (kidney bean) assessed as necrosis of leaf at 100 ppm after 7 days in greenhouse conditions	Phaseolus vulgaris	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2286546
PubChem	76327324

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).